Telomerase, a specialized ribonucleoprotein reverse transcriptase that dire
cts the synthesis of telomeric DNA, is repressed in normal human somatic ce
lls, but is activated in most cancers. Little is known concerning how telom
erase activity is activated and maintained in cancer cells. We have shown p
reviously that inhibition of protein kinase C (PKC) decreases the telomeras
e activity of human nasopharyngeal carcinoma (NPC) cells. Here, we provide
evidence that the decrease of telomerase activity by PKC inhibition is not
mediated by transcriptional down-regulation of hTERT, the catalytic protein
of human telomerase. In vitro phosphorylation studies revealed that exogen
ous addition of PKC-alpha, -betaI, -delta or -zeta led to restoration of te
lomerase activity in the crude extracts of PKC-inhibited NPC cells. However
, depletion of PKC-alpha and -betaI in vivo had no detectable effect on the
telomerase activity of NPC cells. Using antisense oligonucleotides against
individual PKC isotypes, we observed that telomerase activity was inhibite
d only by the antisense oligonucleotide against PKC-zeta but not by those a
gainst PKC-alpha, -betaI or -delta. Taken together, these data demonstrate
that PKC participates in the regulation of telomerase activity by direct or
indirect phosphorylation of telomerase proteins. and that PKC-zeta is the
PKC isotype that functions in vivo in the NPC cells.